Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Anar, T. Inal, I. Ünsal, H. Halilçolar, G. Polat, S. Anar (Izmir, Turkey). The prognostic value of D-dimer in lung carcinoma. Eur Respir J 2013; 42: Suppl. 57, 2918

Member's Comments

No comment yet.

Related content which might interest you: Prognostic factors for survival in lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Algorithm of preoperative N-staging of non-small cell lung cancer Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013 Does IASLC/ATS/ERS classification of lung adenocarcinoma impacts prognosis? Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Added value of EUS-B to EBUS for lung cancer staging Source: International Congress 2015 – Endoscopic ultrasound: an essential tool for interventional pulmonology Year: 2015 Determinants of negative predictive value during EBUS-TBNA in diagnosis/staging of lung cancer Source: International Congress 2015 – Developments in lung cancer diagnosis Year: 2015 Prognostic value of preoperative C-reactive protein in resectable non-small cell lung cancer - 5-years prospective study Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014 Electrospray-mediated local chemotherapy of lung carcinoma in mice Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Surgical treatment outcomes on early-stages of non-small-cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 ALK/EML4 translocation in non-squamous NSCLC and their predictors Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 EBUS-TBNA for nodal restaging and relapse in lung cancer Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Segmentectomy for second lung cancer after lobectomy Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Checkpointinhibition in lung cancer – How to distinguish pseudoprogression from progressive disease Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Neutrophil/lymphocyte ratio as a prognostic marker for curative-intent surgery in non-small cell lung cancer Source: International Congress 2015 – Surgery and lung cancer: results and complications Year: 2015 Futile thoracotomy in lung cancer Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013